ELOXX PHARMACEUTICALS, INC. Amortization of Intangible Assets
ELOXX PHARMACEUTICALS, INC. (ELOX) reported Amortization of Intangible Assets of $24.98 thousand for the 12-month period ending 2015-06-30, per its 10-K filed 2016-10-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2016-10-13
- ELOXX PHARMACEUTICALS, INC. amortization of intangible assets for the quarter ending 2015-06-30 was $0.00, a 100.00% decline year-over-year.
- ELOXX PHARMACEUTICALS, INC. amortization of intangible assets for the quarter ending 2015-03-31 was $0.00, a 100.00% decline year-over-year.
- ELOXX PHARMACEUTICALS, INC. amortization of intangible assets for the quarter ending 2014-12-31 was $0.00, a 100.00% decline year-over-year.
- ELOXX PHARMACEUTICALS, INC. amortization of intangible assets for the quarter ending 2014-09-30 was $24.98K, a 66.37% decline year-over-year.
- ELOXX PHARMACEUTICALS, INC. amortization of intangible assets for fiscal 2015 was $24.98K, a 92.46% decline from fiscal 2014.
- ELOXX PHARMACEUTICALS, INC. amortization of intangible assets for fiscal 2014 was $331.38K, a 13.86% increase from fiscal 2013.
- ELOXX PHARMACEUTICALS, INC. amortization of intangible assets for fiscal 2013 was $291.05K, a 13.85% increase from fiscal 2012.
- ELOXX PHARMACEUTICALS, INC. amortization of intangible assets for fiscal 2012 was $255.64K, a 81.98% increase from fiscal 2011.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month | Amortization of Intangible Assets 168 month | Amortization of Intangible Assets 180 month |
|---|---|---|---|---|---|---|
| 2015-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-10-13 | $0.00 derived: sum of 2 quarters · filed 2016-10-13 | $0.00 derived: sum of 3 quarters · filed 2016-10-13 | $24.98K 10-K · filed 2016-10-13 | ||
| 2015-03-31 | $0.00 10-Q · filed 2015-05-14 | $0.00 derived: sum of 2 quarters · filed 2015-05-14 | $24.98K 10-Q · filed 2015-05-14 | $119.02K derived: sum of 4 quarters · filed 2016-10-13 | ||
| 2014-12-31 | $0.00 10-Q · filed 2015-02-17 | $24.98K 10-Q · filed 2015-02-17 | $119.02K derived: sum of 3 quarters · filed 2016-10-13 | $204.18K derived: sum of 4 quarters · filed 2016-10-13 | ||
| 2014-09-30 | $24.98K 10-Q · filed 2014-11-14 | $119.02K derived: sum of 2 quarters · filed 2016-10-13 | $204.18K derived: sum of 3 quarters · filed 2016-10-13 | $282.09K derived: sum of 4 quarters · filed 2016-10-13 | ||
| 2014-06-30 | $94.04K derived: 10-K 12 month − 10-Q 9 month · filed 2016-10-13 | $179.20K derived: sum of 2 quarters · filed 2016-10-13 | $257.11K derived: sum of 3 quarters · filed 2016-10-13 | $331.38K 10-K · filed 2016-10-13 | ||
| 2014-03-31 | $85.16K 10-Q · filed 2015-05-14 | $163.07K derived: sum of 2 quarters · filed 2015-05-14 | $237.34K 10-Q · filed 2015-05-14 | $328.41K derived: sum of 4 quarters · filed 2015-10-09 | ||
| 2013-12-31 | $77.91K 10-Q · filed 2015-02-17 | $152.18K 10-Q · filed 2015-02-17 | $243.25K derived: sum of 3 quarters · filed 2015-10-09 | $314.10K derived: sum of 4 quarters · filed 2015-10-09 | ||
| 2013-09-30 | $74.27K 10-Q · filed 2014-11-14 | $165.34K derived: sum of 2 quarters · filed 2015-10-09 | $236.19K derived: sum of 3 quarters · filed 2015-10-09 | $302.39K derived: sum of 4 quarters · filed 2015-10-09 | ||
| 2013-06-30 | $91.07K derived: 10-K 12 month − 10-Q 9 month · filed 2015-10-09 | $161.92K derived: sum of 2 quarters · filed 2015-10-09 | $228.12K derived: sum of 3 quarters · filed 2015-10-09 | $291.05K 10-K · filed 2015-10-09 | $1.21M 10-K · filed 2013-09-11 | |
| 2013-03-31 | $70.84K 10-Q · filed 2014-05-09 | $137.05K derived: sum of 2 quarters · filed 2014-05-09 | $199.97K 10-Q · filed 2014-05-09 | $271.90K derived: sum of 4 quarters · filed 2014-09-29 | ||
| 2012-12-31 | $66.20K 10-Q · filed 2014-02-14 | $129.13K 10-Q · filed 2014-02-14 | $201.06K derived: sum of 3 quarters · filed 2014-09-29 | |||
| 2012-09-30 | $62.92K 10-Q · filed 2013-11-14 | $134.85K derived: sum of 2 quarters · filed 2014-09-29 | ||||
| 2012-06-30 | $71.93K derived: 10-K 12 month − 10-Q 9 month · filed 2014-09-29 | $255.64K 10-K · filed 2014-09-29 | $921.50K 10-K/A · filed 2012-10-26 | |||
| 2012-03-31 | $183.71K 10-Q · filed 2013-05-15 | |||||
| 2011-06-30 | $140.48K 10-K · filed 2013-09-11 | |||||
| 2010-06-30 | $124.02K 10-K/A · filed 2012-10-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Tevogen Inc. (TVGN) | United States | $0.049B |